Jubilant Pharmova · NSE: JUBLPHARMA · BSE: 530019
Q4 FY26 results · Jan–Mar 2026
Jubilant Pharmova reported revenue from operations of ₹2,290.00 crore (up 18.7% from Q4 FY25) and net profit of ₹119.30 crore (down 21.2% from Q4 FY25) for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,290.00 | 1,928.80 | +18.7% | 2,122.50 | +7.9% |
| Other income | 23.70 | 11.90 | +99.2% | 20.50 | +15.6% |
| Total income | 2,313.70 | 1,940.70 | +19.2% | 2,143.00 | +8.0% |
| Profit before tax | 176.00 | 206.10 | −14.6% | 93.50 | +88.2% |
| Net profit for the period | 119.30 | 151.30 | −21.2% | 55.80 | +113.8% |
| Attributable to shareholders of the company | 119.40 | 153.60 | −22.3% | 55.90 | +113.6% |
| EPS, basic (₹) | 7.55 | 9.71 | −22.2% | 3.52 | +114.5% |
| Net margin (%) | 5.2 | 7.8 | 2.6 |
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 70.30 | 217.30 | −67.6% | 67.30 | +4.5% |
| Other income | 0.50 | 17.90 | −97.2% | 0.40 | +25.0% |
| Total income | 70.80 | 235.20 | −69.9% | 67.70 | +4.6% |
| Profit before tax | 4.10 | 23.50 | −82.6% | 10.10 | −59.4% |
| Net profit for the period | 57.20 | 13.60 | +320.6% | 6.60 | +766.7% |
| EPS, basic (₹) | 3.59 | 0.86 | +317.4% | 0.42 | +754.8% |
| Net margin (%) | 81.4 | 6.3 | 9.8 |
Consolidated
- Filed with BSE
- 22 May 2026, 20:04 IST
- Board meeting
- 22 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 22 May 2026, 20:04 IST
- Board meeting
- 22 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE